Massachusetts Financial Services Co. MA Has $857,000 Stock Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Massachusetts Financial Services Co. MA cut its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 2.9% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 178,847 shares of the biopharmaceutical company’s stock after selling 5,334 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Vanda Pharmaceuticals were worth $857,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in VNDA. Verition Fund Management LLC raised its stake in shares of Vanda Pharmaceuticals by 7.8% in the third quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 2,927 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Vanda Pharmaceuticals by 0.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 596,210 shares of the biopharmaceutical company’s stock valued at $2,796,000 after purchasing an additional 3,473 shares during the last quarter. Franklin Resources Inc. boosted its stake in Vanda Pharmaceuticals by 8.8% in the third quarter. Franklin Resources Inc. now owns 55,226 shares of the biopharmaceutical company’s stock worth $266,000 after purchasing an additional 4,449 shares in the last quarter. Brandywine Global Investment Management LLC grew its holdings in shares of Vanda Pharmaceuticals by 13.9% during the fourth quarter. Brandywine Global Investment Management LLC now owns 39,390 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 4,820 shares during the last quarter. Finally, SG Americas Securities LLC increased its stake in shares of Vanda Pharmaceuticals by 26.8% in the fourth quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 5,459 shares in the last quarter. 88.14% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of Vanda Pharmaceuticals stock in a transaction dated Friday, February 28th. The shares were acquired at an average cost of $4.76 per share, for a total transaction of $47,600.00. Following the transaction, the chief executive officer now directly owns 2,361,730 shares of the company’s stock, valued at approximately $11,241,834.80. This trade represents a 0.43 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders acquired a total of 32,000 shares of company stock valued at $151,180 over the last ninety days. Insiders own 8.90% of the company’s stock.

Vanda Pharmaceuticals Stock Down 1.2 %

VNDA stock opened at $4.14 on Wednesday. Vanda Pharmaceuticals Inc. has a twelve month low of $3.86 and a twelve month high of $6.75. The company has a market cap of $241.43 million, a P/E ratio of -12.94 and a beta of 0.72. The business has a fifty day moving average of $4.65 and a 200-day moving average of $4.71.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.06. The firm had revenue of $53.19 million during the quarter, compared to analysts’ expectations of $51.00 million. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. As a group, equities research analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

VNDA has been the topic of several research reports. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Vanda Pharmaceuticals in a research report on Tuesday, April 1st. StockNews.com started coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They set a “hold” rating on the stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.